Contact Us

This is a promotional website intended for healthcare professionals in the UK and Ireland only.

For enquiries about ordering BRUKINSA (zanubrutinib) in England, Scotland or Wales, please contact [email protected].

For enquiries about ordering BRUKINSA (zanubrutinib) in Northern Ireland or Ireland, please contact [email protected]

If you would like to speak to our pharmacy liaison manager, please contact Nisa Khan [email protected]

For medical information, please contact: UK: 08004320266, Ireland: 1800946589 or email: [email protected]

If you have any general questions, please contact [email protected].

Adverse events should be reported

United Kingdom (incl. Northern Ireland): Healthcare Professionals are asked to report any suspected adverse reactions via Yellow Card Scheme found at www.mhra.gov.uk/yellowcard.
Ireland: Healthcare Professionals are asked to report any suspected adverse reactions via HPRA.

All adverse events (UK and Ireland) should also be reported to BeiGene at [email protected]; (UK: 08009176799; Ireland: 1800812061).

For medical information, please contact: UK: 08004320266, Ireland: 1800946589 or email: [email protected]

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

November 2023 [1023-BRU-PRC-088]

Back to top

Brukinsa®▼ UK and Ireland healthcare professional website

This website contains information on BRUKINSA (zanubrutinib) and is intended for healthcare professionals in the UK and Ireland only.

To direct you to the most appropriate information, please confirm you are a UK or Ireland Healthcare Professional.

If you are not a UK or Ireland Healthcare Professional, you will be directed to the BRUKINSA Patient Information leaflet.

Are you a UK or Ireland Healthcare Professional?

0823-BRU-PRC-184 | September 2023

No, I am not